---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-016797"
form_type: "8-K/A"
ticker: "TVGN"
cik: "0001860871"
company_name: "Tevogen Bio Holdings Inc."
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T05:46:06.843509+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tevogen Bio's audited FY2023 shows $60.5M net loss, going concern doubt

## Summary
- Net loss of $60.5M in 2023 vs $22.0M in 2022; accumulated deficit $99.7M.
- Cash of $1.05M as of Dec 31, 2023; management cites substantial doubt about going concern.
- Convertible promissory notes total $94.9M, with $80.7M current; fair value change of $50.4M recorded as loss.
- Total operating expenses $8.8M (R&D $4.4M, G&A $4.4M), down from $13.7M in 2022.
- Business combination with Semper Paratus closed Feb 14, 2024; post-merger financing included $2M Series A and $1.2M Series A-1 preferred.

## SEC filing metadata
- accession: 0001493152-24-016797
- form_type: 8-K/A
- ticker: TVGN
- cik: 0001860871
- company_name: Tevogen Bio Holdings Inc.
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860871/000149315224016797/0001493152-24-016797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860871/000149315224016797/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-016797
- JSON: https://secwatch.observer/filing/0001493152-24-016797.json
- Plain text: https://secwatch.observer/filing/0001493152-24-016797.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.